Status:
UNKNOWN
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
Lead Sponsor:
Hebei Medical University Third Hospital
Conditions:
Giant Cell Tumor of Bone
Eligibility:
All Genders
14-60 years
Phase:
PHASE3
Brief Summary
Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use ...
Detailed Description
Giant cell tumor of bone (GCTb) is an aggressive, benign bone tumor. GCTb, which was first defined by Cooper and Travers, can produce pulmonary metastasis, albeit rarely (1-6%). GCTb constitutes 5% of...
Eligibility Criteria
Inclusion
- Giant cell tumor of bone patients confirmed by clinical, medical imaging and Pathology.
Exclusion
- (1) less than 14 patients; 2) pregnant patients; 3) A patient who receives other medications during treatment.
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03259152
Start Date
May 1 2016
End Date
May 1 2019
Last Update
August 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhuang Zhou
Shijiazhuang, Hebei, China, 050000